Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del)

Stem Cell Res. 2023 Feb:66:103001. doi: 10.1016/j.scr.2022.103001. Epub 2022 Dec 8.

Abstract

Fabry disease (FD) is a lysosomal storage disorder caused by mutations in GLA gene. Here, GLA mutation (1268fs*1 (c.803_806del)) of FD iPSCs was corrected using the CRISPR-Cas9 gene editing system. The corrected (cor) FD-iPSCs retained normal morphology, karyotype, expression of pluripotency-associated markers, trilineage differentiation potential, and GLA activity. Thus, FD(cor)-iPSCs can be used as valuable tools to study the mechanism how GLA mutation1268fs*1 induces various pathophysiologic phenotypes in FD patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems / genetics
  • Fabry Disease* / genetics
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Mutation / genetics
  • alpha-Galactosidase / genetics
  • alpha-Galactosidase / metabolism

Substances

  • alpha-Galactosidase